Total amount raised
$643 Millions
Latest funding date
3/1/2021
Location
Insitro has successfully raised significant funding through multiple rounds, achieving a valuation that places it among the elite unicorns in the biotech industry. The company leverages a machine learning-driven platform to revolutionize drug discovery and development.
Keep reading to explore the intricacies of Insitro's fundraising journey and the investors backing this innovative platform.
What Is Insitro?
Insitro, founded in 2018 by Daphne Koller, is based in South San Francisco, California. The company focuses on revolutionizing drug discovery and development through the integration of machine learning and high-throughput biology.
Insitro's platform combines in vitro cellular data with clinical data to accelerate the development of new medicines. Their therapeutic programs target areas such as metabolism, oncology, and neuroscience.
With a team of 251-500 employees, Insitro is making significant strides in the biotech industry, leveraging data-driven approaches to transform traditional drug discovery processes.
How Much Funding Has Insitro Raised?
- Series A
- Amount Raised: $100M
- Date: May 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish the foundational technology and initial team for Insitro's machine learning-driven drug discovery platform.
- Series B
- Amount Raised: $143M
- Date: May 2020
- Lead Investors: Andreessen Horowitz
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the company's capabilities in high-throughput biology and machine learning integration.
- Series C
- Amount Raised: $400M
- Date: March 2021
- Lead Investors: CPP Investments
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further expand Insitro’s platform capabilities and pipeline, providing resources to access enabling datasets, technologies, platforms, and potential in-licensed assets.
Total Amount Raised: $643M. Current Valuation: Not publicly disclosed.
Key Investors
- CPP Investments
- Details: CPP Investments is a professional investment management organization that invests the funds of the Canada Pension Plan. They focus on long-term investments to ensure sustainable returns.
- Investment Focus Areas: Healthcare, technology, infrastructure.
- Notable Investments: Enbridge, Alibaba, Glencore.
- Andreessen Horowitz
- Details: Andreessen Horowitz is a private venture capital firm known for investing in technology companies at various stages. They have a strong track record of backing successful startups.
- Investment Focus Areas: Technology, healthcare, fintech.
- Notable Investments: Facebook, Airbnb, Slack.
- BlackRock
- Details: BlackRock is an American global investment management corporation. They manage assets across a broad range of sectors and are one of the largest asset managers in the world.
- Investment Focus Areas: Technology, healthcare, financial services.
- Notable Investments: Apple, Microsoft, Alphabet.
- ARCH Venture Partners
- Details: ARCH Venture Partners is a venture capital firm that focuses on early-stage technology companies. They have a history of investing in groundbreaking biotech firms.
- Investment Focus Areas: Biotechnology, life sciences, technology.
- Notable Investments: Illumina, Alnylam Pharmaceuticals, Juno Therapeutics.
- GV (formerly Google Ventures)
- Details: GV is the venture capital investment arm of Alphabet Inc. They invest in companies across various sectors, leveraging their expertise in technology and innovation.
- Investment Focus Areas: Technology, life sciences, healthcare.
- Notable Investments: Uber, Nest, Slack.
What's Next for Insitro?
Insitro stands at the cusp of significant growth, driven by its machine learning-driven platform and strategic partnerships. The recent $400 million Series C financing will enable the company to expand its platform capabilities and pipeline, accessing enabling datasets and technologies. Collaborations with industry giants like Gilead and Bristol Myers Squibb highlight the vast opportunities in areas such as NASH and ALS.
Future fundraising seems promising, with continued support from long-term investors like CPP Investments and new backers such as Temasek and Softbank. However, Insitro must navigate the complexities of integrating machine learning into drug discovery and managing multiple high-stakes collaborations. The biotech landscape is rapidly evolving, and maintaining a competitive edge will be crucial for sustained success.
Use Clay to Get Funding Data
Sales professionals, take your prospecting to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Insitro and gather other critical business insights. Sign up for free today and unlock the potential of data-driven sales strategies.
